The role of interleukin-17 inhibition in systemic lupus erythematosus-paradoxical hindrance or new therapeutic potential? Results from a systematic literature review and mendelian randomization - PubM
6 hours ago
- #Interleukin-17 inhibition
- #Mendelian randomization
- #Systemic lupus erythematosus
- IL-17 inhibitors (IL-17i) like secukinumab, bimekizumab, brodalumab, and ixekizumab are being studied for systemic lupus erythematosus (SLE) treatment.
- Case reports show secukinumab used for active SLE, mainly cutaneous disease and arthritis, but efficacy data is limited and heterogeneous.
- New-onset SLE after IL-17i treatment is rare: no cases in secukinumab trials, one with brodalumab, six with secukinumab, and none for bimekizumab or ixekizumab-induced SLE.
- Patients with drug-induced SLE from IL-17i generally recover after stopping the drug and require only symptomatic management.
- Further research, including translational studies and clinical trials, is needed to understand IL-17's role in SLE and IL-17i's therapeutic potential.